CTLA-4/CD152 Immune Checkpoint Inhibitors

CTLA-4/CD152 immune checkpoint inhibitors are a kind of drug, targeting CTLA-4/CD152 immune checkpoint molecule. Most of CTLA-4/CD152 immune checkpoint inhibitors are antibodies. CTLA-4/CD152, as a nagtive immune checkpoint signal is expressed exclusively on T cells where it primarily regulates the amplitude of the early stages of T cell activation. The CTLA-4/CD152 can reduce immunity for cancer, so CTLA-4/CD152 immune checkpoint inhibitors is applied to enhance cancer immunity. Some immune checkpoint inhibitors have been developped for different cancers, such as Tremelimumab and Ipilimumab for Melanoma, Non-small cell lung cancer……

CTLA-4/CD152 Immune Checkpoint Inhibitors: Developments

Disease CTLA-4/CD152 immune checkpoint inhibitors research development
Melanoma Tremelimumab —— a phase III study evaluated overall survival (OS) and other safety and efficacy end points in patients with advanced melanoma treated with this CTLA-4/CD152 immune checkpoint inhibitors drug or standard-of-care chemotherapy(Ribas et al. 2013).
Ipilimumab —— as a CTLA-4/CD152 immune checkpoint inhibitors drug, is the first therapy to demonstrate a survival benefit for patients with metastatic melanoma, it was approved by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in 2010 (Drew M. Pardoll et al. 2012)
Non-small cell lung cancer Ipilimumab —— A phase II study in NSCLC assessed the activity of CTLA-4/CD152 immune checkpoint inhibitors drug ipilimumab (Lynch et al. 2012).
Tremelimumab —— a phase III trial of durvalumab (MEDI4736) with or without tremelimumab (CTLA-4/CD152 immune checkpoint inhibitors drug) versus standard-of-care chemotherapy was conducted in patients with NSCLC (MYSTIC, NCT02453282).
Small cell lung cancer Ipilimumab —— This phase 2 study evaluated CTLA-4/CD152 immune checkpoint inhibitors drug ipilimumab+paclitaxel (Taxol)/carboplatin in extensive-disease-small-cell lung cancer (ED-SCLC, Reck et al. 2013).
Cervical cancer Ipilimumab (Yervoy®) —— a CTLA-4/CD152 immune checkpoint inhibitors drug made by Bristol-Myers Squibb, is being tested in two clinical trials for patients with cervical cancer: a phase II study of ipilimumab for HPV+ cervical cancer that is metastatic or recurrent (NCT01693783), and a phase I study of chemoradiation followed by ipilimumab for patients with locally advanced cervical cancer (NCT01711515).
Tremelimumab—— a CTLA-4/CD152 immune checkpoint inhibitors drug, is being tested in combination MEDI4736, an anti-PD-L1 antibody,, in a phase I trial for patients with six kinds of cancer, including cervical cancer (NCT01975831).
Colorectal cancer Ipilimumab (Yervoy®) —— a phase I/II trial of nivolumab (Opdivo®), CTLA-4/CD152 immune checkpoint inhibitors drug, +/- ipilimumab, a CTLA-4/CD152 immune checkpoint inhibitor, in patients with recurrent and metastatic colon cancer (NCT02060188).
Tremelimumab —— a phase I trial of tremelimumab (CTLA-4/CD152 immune checkpoint inhibitors drug) and MEDI4736 (PD-L1 immune checkpoint inhibitor) was conducted in patients with advanced solid tumors, including colorectal cancer (NCT01975831).
Kidney cancer Ipilimumab (Yervoy), —— a phase III study of nivolumab (Opdivo), a PD-1 immune checkpoint inhibitors drug, with ipilimumab (Yervoy), a CTLA-4/CD152 immune checkpoint inhibitor, both made by Bristol-Myers Squibb, versus sunitinib (Sutent), for patients with previously untreated advanced or metastatic renal cell carcinoma (NCT02231749). Tremelimumab —— a phase I trial of tremelimumab (CTLA-4/CD152 immune checkpoint inhibitor) and MEDI4736 (PD-L1 immune checkpoint inhibitor), made by MedImmune, for patients with advanced solid tumors, including renal carcinoma (NCT01975831).
Liver cancer Tremelimumab —— CTLA-4/CD152 immune checkpoint inhibitors drug developed by MedImmune/AstraZeneca, is being tested along with chemoembolization or ablation in a phase I clinical trial for patients with liver cancer (NCT01853618).
Lymphoma Ipilimumab —— a phase I study of ipilimumab (CTLA-4/CD152 immune checkpoint inhibitors drug) was conducted in combination with rituximab in patients with relapsed or refractory CD20+ B-cell lymphoma (NCT01729806)

CTLA-4/CD152 Immune Checkpoint Inhibitors: Relatives

PD1/PDCD1/CD279 immune checkpoint inhibitors PD-L1/B7-H1/CD274 immune checkpoint inhibitors
B7-H3/CD276 immune checkpoint inhibitors Indoleamine 2,3‑dioxygenase/IDO immune checkpoint inhibitors
KIR immune checkpoint inhibitors LAG3 / CD223 immune checkpoint inhibitors
Immune Checkpoint
What is immune checkpoint?
Immune checkpoint targets
Immune checkpoint blockade: blocking antibodies
Immune checkpoint detection: antibodies
Immune checkpoint proteins
Immune checkpoint inhibitors
Immune checkpoint therapy
Immune checkpoint pathways
PD1 / PDCD1 / CD279 immune checkpoint
VISTA / B7-H5 / GI24 immune checkpoint